Molecular profiling. Mutations found using a 36-gene NGS panel in the testing cohort, represented according to the presence or absence of clinical events of the primary outcome. Each column represents 1 sequenced patient. Eighty percent of patients with events had additional mutations vs 41% of patients without events. MF, myelofibrosis; ND, not determined.